First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of ARV-102, a PROTAC LRRK2 degrader, in healthy volunteers
Authors: Sergey Aksenov, Ana LC Zaninotto, Thomas Storz, Y. Folami, C. Lubeski, Marsha MacDougall, Adam W. Hendricson, Sandra G. P. J. Korsten, Philip H. C. Kremer, Angela M. Cacace
Journal: Parkinsonism & Related Disorders
Publication year: 2025